Oral ePoster

B I Keywords: i b Esophageal adenocarcinoma, IL-33, Rat B OPP-0036 b B Machine learning models in the prediction of one-year mortality in patients with advanced hepatocellular cancer treated with immunotherapy b Thomas Ka Luen Lui, Michael Ka Shing Cheung and Wai Keung Leung I Department of Medicine, University of Hong Kong, Hong Kong, China i B I Background and Aim: i b Immunotherapy is a new promising treatment for patients with advanced hepatocellular carcinoma (HCC). All patients received concurrent adjuvant chemotherapy with either FOLFIRINOX, gemcitabine/abraxane or targeted therapy as clinically indicated, with a minimum of 3-monthly clinical follow-up. B I Results: i b A total of six patients (4 F, median age 64, 52-73 years) underwent combined therapy with 32P implantation at 3 to 8 months after diagnosis (median 5 months). Symptoms included abdominal distension in 43 patients (86%), diarrhea in 25 patients (50%), constipation in 8 patients (16%), BMI 17, serum albumin level 3.7 mg/dL, and IVH requirement in 21 patients (42%). B I Results: i b Among the 4469 patients with immune-mediated diseases (including 3172 rheumatology patients, 613 dermatology patients, and 554 inflammatory bowel disease patients) included 257 and 204 patients who developed serious and opportunistic infections, respectively. B I Results: i b IL-7R levels in PDAC patients were significantly higher than levels in healthy control patients, benign pancreatic disease patients, and individuals with other malignancies. [Extracted from the article] Copyright of Journal of Gastroenterology & Hepatology is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)